Jazz Pharmaceuticals heads into the back half of June with short sellers continuing their retreat and the Street firmly bullish — yet the stock has drifted lower since the last note, raising a quiet question about whether analyst enthusiasm is getting ahead of the price action.
The short covering story remains intact, and the numbers have accelerated. Short interest has dropped another 12.9% over the past week to 6.8% of the free float — the lowest reading in the 30-day window and down sharply from the 8.5% level that prevailed in early May. That's roughly 640,000 fewer shares short than a week ago. The borrow market remains fully relaxed: availability is running at nearly 693% — well over six shares available for every one currently lent out — and cost to borrow has eased to 0.43%, near the low end of its recent range. There is no squeeze dynamic here. The ORTEX short score has also drifted down from 51.8 on June 8 to 48.9 today, moving from a modestly bearish read to just below neutral, consistent with the broader unwinding of negative positioning.
Options tell a similarly calm story. The put/call ratio is 0.78, almost exactly in line with its 20-day average of 0.77 — a z-score of just 0.16. That's well within normal territory, implying neither elevated hedging demand nor unusual call speculation. The 52-week range for the PCR runs from 0.09 to 1.54, and the current reading is squarely in the middle. Positioning here reads as neutral, not charged in either direction.
The Street, however, is anything but neutral. The analyst recommendation differential ranks in the 100th percentile — as lopsided a bull consensus as the universe contains. The most recent move came from BofA's Jason Gerberry, who lifted his target from $281 to $307 on June 10, extending a cluster of upgrades and target hikes that followed the May 6 Q1 print. UBS upgraded to Buy from Neutral with a $307 target in May; Piper Sandler moved to $301; Wells Fargo and TD Cowen both raised targets above $265. The mean target across nine Buy-rated analysts is $257, which implies about 13% upside from the June 16 close of $226.88. The one dissenting note is Bernstein, which initiated at Market Perform with a $229 target — essentially flat to where the stock trades now. Valuation multiples remain modest: the stock trades at roughly 8.9x trailing earnings and 8.0x EV/EBITDA, both compressing slightly over the past 30 days despite the target-price inflation. Bulls anchor on Epidiolex growth and zanidatamab pipeline progress; bears flag generic erosion in the oxybate franchise and execution risk in oncology.
One feature worth watching is the insider register. The net 90-day insider activity shows roughly $7.1 million in net sales — dominated by founder and chairman Bruce Cozadd, who has sold shares in three separate tranches since April 1. The Chief Commercial Officer and Chief Legal Officer have also trimmed. All transactions carry low significance scores, and the sales pattern looks routine rather than distressed, but the sustained one-way flow from senior insiders into a rising stock is a data point the shorts who remain will likely be watching.
The next scheduled earnings event is August 5. That print will be the first real test of whether the Street's sharply upgraded targets can find fundamental support — particularly on oxybate revenue trends and any update on zanidatamab development timelines.
See the live data behind this article on ORTEX.
Open JAZZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
